PARP1 and cardiomyopathy: PARP-1 inhibitors have been effective in the treatment of ischemia/reperfusion damage after stroke or brain, myocardial, hepatic, and renal ischemia/reperfusion injury, other acute forms of cardiomyopathies and heart failure, tissue injury in response to septic and hemorrhagic shock, as well as acute lung inflammation, peritonitis, and pancreatitis.